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The discovery and development of novel inhibitors with activity against variants of human 
immunodeficiency virus type 1 (HIV-1) is pivotal for overcoming treatment failure. As our ongoing work 
on research of anti-HIV-1 inhibitors, 32 N-arylsulfonyl-3-acylindole benzoyl hydrazone derivatives were 
prepared by introduction of the hydrazone fragments on the N-arylsulfonyl-3-acylindolyl skeleton and 
preliminarily screened in vitro as HIV-1 inhibitors for the first time. Among of all the reported analogues, 
eight compounds exhibited significant anti-HIV-1 activity, especially N-(3-nitro)phenylsulfonyl-3-
acetylindole benzoyl hydrazone (18) and N-(3-nitro)phenylsulfonyl-3-acetyl-6-methylindole benzoyl 
hydrazone (23) displayed the most potent anti-HIV-1 activity with EC50 values of 0.26 and 0.31 μg/mL,  
and TI values of >769.23 and >645.16, respectively. It is noteworthy that introduction of R3 as the 
methyl group and R2 as the hydrogen group could result in more potent compounds. This suggested that 
introduction of R3 as the methyl group could be taken into account for further preparation of these kinds 
of compounds as anti-HIV-1 agents.
Keywords: Benzoyl hydrazone. Human immunodeficiency virus type-1. Inhibitor of virus replication. 
Anti-HIV-1 agent.
INTRODUCTION
Acquired immunodeficiency syndrome (AIDS) is 
mainly caused by human immunodeficiency virus type 1 
(HIV-1) infection and remains one of the biggest medical 
barriers for human health, since it was first reported in 
1981 (Gottlieb et al., 1981). The reverse transcriptase 
(RT) of the HIV-1 plays a significant role in the viral 
replication process, which makes it a pivotal target for 
anti-HIV-1 inhibitor discovery (Jonckheere, Anné, De 
Clercq, 2000; Yisma et al., 2014). Although numerous 
RT inhibitors, including primarily the nucleoside/
nucleotide RT inhibitors (NRTIs), e.g., zidovudine, and 
non-nucleoside RT inhibitors (NNRTIs), e.g., nevirapine, 
delavirdine and efavirenz, have been developed, like 
other anti-HIV inhibitors, effectiveness of now approved 
NRTIs and NNRTIs have been hampered because of 
the fast development of resistance (Boone, 2006; De 
Clercq, 2002; Sluis-Cremer, Wainberg, Schinazi, 2015; 
Yu et al., 2011). It is estimated that 36.9 million people 
(including 2.6 million children) were living with HIV 
infection in the year 2014 according to UNAIDS-2015 
report, and 1.2 million people died due to HIV as well 
as related diseases (Chander et al., 2016). To circumvent 
this challenge, there is an urgent need to discover and 
develop safe, green, efficient, selective and novel anti-
HIV inhibitors having significant potency against drug-
resistant RT viral strains as well as less toxicity (Chander 
et al., 2016; Huang et al., 2007; Polanski et al., 2006; 
Safakish et al., 2017). 
Hydrazones are excellent candidates for the 
research of antiprotozoal agents (Carvalho et al., 2014; 
de Sá Alves, Barreiro, Fraga, 2009), multidentate ligands 
(Bessy Raj, Prathapachandra Kurup, Suresh, 2008), 
pesticidal agents (Che et al., 2013b; Guo et al., 2012) 
and gelatinase inhibitors (Yang et al., 2016). Meanwhile, 
N-arylsulfonylindoles or N-arylsulfonyl-3-acylindoles are 
excellent candidates for the study of anti-HIV-1 inhibitors 
(Che et al., 2016; Fan et al., 2009; Ran et al., 2010), and 
especially some N-arylsulfonyl-3-acetylindoles showed 
potent anti-HIV-1 activity. Nevertheless, the anti-HIV-1 
activity of the N-arylsulfonyl-3-acylindole benzoyl 
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hydrazones has not been previously published. Inspired by 
these previous observations, and the goal in this program is 
to discover new compounds with potent biological activity 
(Che et al., 2013a; Che et al., 2015; Che et al., 2016; Xu, 
Che, Wang, 2011), we report here the results of the anti-
HIV-1 activity of 32 N-arylsulfonyl-3-acylindole benzoyl 
hydrazone derivatives for the first time.
RESULTS AND DISCUSSION
Chemistry
32 N-Arylsulfonyl-3-acylindole benzoyl hydrazone 
analogs (1-32, Figure 2) were smoothly synthesized as 
shown in Scheme 1. N-Arylsulfonyl-3-acetylindoles (A) 
reacted with the corresponding benzoyl hydrazides (B) 
in the presence of AcOH at reflux, and compounds 1-32 
were prepared, as well as characterized by satisfactory 
proton nuclear magnetic resonance (1H NMR), carbon 
nuclear magnetic resonance (13C NMR), electrospray ion 
trap mass spectrometry (ESI-TRAP-MS), high-resolution 
mass spectra (HR-MS), as well as melting point (Che et 
al., 2013b). Owing to the steric hindrance, the substituents 
on the C-N bond of all compounds adopted a trans 
configuration (E configuration) (Carvalho et al., 2014; 
Che et al., 2013b; Lourenço et al., 2008).
Interestingly, all reactants dissolved well in 
anhydrous ethanol in the beginning of the reaction. As the 
reaction progressed, some insoluble species were gradually 
precipitated out, as well as at the end of the reaction, a large 
amount of solid accumulated in the bottom of the flask. 
As a result of this behavior, all the desired N-arylsulfonyl-
3-acylindole benzoyl hydrazone analogs (1-32) could be 
obtained by filtration. This procedure imbues the synthetic 
methodology with green credentials.
Moreover, target compounds 1-32 were analysed by 
reverse phase high-performance liquid chromatography 
(RP-HPLC), and all compounds purity were >95%.
Biological activities
As our ongoing work on research of anti-HIV-1 
inhibitors, purified and characterized N-arylsulfonyl-
3-acylindole benzoyl hydrazones 1-32 were screened 
in vitro for their inhibitory activity against HIV-1 
replication in acutely infected C8166 cells, and 3′-azido-
3′-deoxythymidine (AZT) was used as a positive control 
presented in Table I.
The results of anti-HIV-1 viral replication assay 
revealed that, out of thirty-two evaluated compounds, two 
(18 and 23) showed significant anti-HIV-1 activity (EC50 
values of 0.26 and 0.31 μg/mL, TI values of >769.23 and 
>645.16, respectively), six (10, 14, 19, 20, 24 and 27) 
showed moderate anti-HIV-1 activity (EC50 values of 
1.02, 0.52, 0.49, 1.65, 0.67 and 0.50 μg/mL, TI values 
of 116.33, >384.61, >408.16, >121.21, >298.50 and 
>249.86, respectively), while the rest of tested compounds 
displayed weak anti-HIV-1 activity (EC50 values of 1.71 to 
FIGURE 1 - Structures of currently approved NRTIs and NNRTIs by the U.S. FDA.
 SCHEME 1 - Synthetic route for the preparation of N-arylsulfonyl-3-acylindole benzoyl hydrazone derivatives 1-32.
Discovery of N-arylsulfonyl-3-acylindole benzoyl hydrazone derivatives as anti-HIV-1 agents
Braz. J. Pharm. Sci. 2018;54(4):e17543 Page 3 / 7
FIGURE 2 - Chemical structures of N-arylsulfonyl-3-acylindole benzoyl hydrazone derivatives 1-32.
Zhiping C., Yuee T., Shengming L., Mei H., Genqiang C.
Braz. J. Pharm. Sci. 2018;54(4):e17543Page 4 / 7
TABLE I - Anti-HIV-1 activity of n-arylsulfonyl-3-acylindole benzoyl hydrazone derivatives 1-32 in vitroa.
 
Compd R1 R2 R3 CC50b(μg/mL) EC50c(μg/mL) TId
1 H 4-Me H 89.93 11.02 8.16
2 H 4-OMe H 192.02 3.02 63.58
3 H 4-NHAc H 18.31 1.71 10.70
4 H 4-Cl H 53.15 9.92 5.36
5 H 3-NO2 H 27.09 4.06 6.67
6 H 3-NO2, 4-Cl H 1.77 59.99 0.03
7 6-Me 4-Me H 41.74 8.25 5.06
8 6-Me 4-OMe H 74.86 3.66 20.45
9 6-Me 4-Cl H 0.68 3.64 0.19
10 6-Me 3-NO2 H 118.66 1.02 116.33
11 5-CN 4-Me H 123.68 3.13 39.51
12 5-CN 3-NO2 H 21.47 3.13 6.85
13 5-NO2 4-Me H 73.09 20.82 3.51
14 H H Me >200 0.52 >384.61
15 H 4-Me Me 8.79 0.93 9.45
16 H 4-OMe Me 1.30 0.16 8.13
17 H 4-Cl Me >200 125.16 >1.60
18 H 3-NO2 Me >200 0.26 >769.23
19 6-Me H Me >200 0.49 >408.16
20 6-Me 4-Me Me >200 1.65 >121.21
21 6-Me 4-OMe Me >200 12.37 >16.16
22 6-Me 4-Cl Me 96.71 2.51 38.53
23 6-Me 3-NO2 Me >200 0.31 >645.16
24 5-CN H Me >200 0.67 >298.50
25 5-CN 4-Me Me >200 59.99 >3.33
26 5-CN 4-Cl Me 19.76 11.72 1.68
27 5-NO2 H Me 124.93 0.50 249.86
28 5-NO2 4-Me Me >200 2.55 >78.43
29 5-NO2 4-Cl Me >200 7.27 >27.51
30 H H Et >200 14.53 >13.76
31 H H n-pentyl >200 38.23 >5.23
32 H 4-Me n-pentyl >200 52.23 >3.83
AZTe \ \ \ 1139.47 0.00324 351688.3
aValues are means of two separate experiments (the values exhibited standard deviation (SD) less than ±5% from mean). bCC50 
(50% cytotoxic concentration), concentration of drug that causes 50% reduction in total C8166 cell number. cEC50 (50% effective 
concentration), concentration of drug that reduces syncytia formation by 50%. dIn vitro therapeutic index (CC50 value/EC50 value). 
eAZT was used as a positive control.
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>125.16 µg/mL, except 16, the EC50 value of 0.16 μg/mL, 
and TI values of 0.03 to 78.43).
In order to elucidate the anti-HIV-1 activity of 
compounds 1-32 at a molecular basis and to reveal 
structural features critical for their anti-HIV-1 activity, a 
brief investigation of structure activity relationship (SAR) 
was determined, which revealed how the substituents on 
1-32 were related to the anti-HIV-1 activity. In general, (1) 
R3 = Me was more vital for the anti-HIV-1 activities than 
R3 = H, Et, or n-pentyl. For example, when R1 and R2 were 
H, introduction of R3 as the methyl group could lead to 
the pronounced compound (14 vs 30 and 31, EC50 values 
of 0.52, 14.53 and 38.23 μg/mL, TI values of >384.61, 
>13.76 and >5.23, respectively; that is, the TI value of 
14 was close to 28 times of that of 30 and was more than 
73 times of that of 31). (2) When R1 = H or 6-Me and 
R2 = 3-NO2, compounds with R
3 = Me exhibited significant 
inhibitory potential against the HIV viral replication 
(18 vs 5, EC50 values of 0.26 and 4.06 μg/mL, TI values 
of >769.23 and 6.67, respectively, especially the TI value 
of 18 was more than 115 times of that of 5; 23 vs 10, EC50 
values of 0.31 and 1.02 μg/mL, TI values of >645.16 and 
116.33, respectively). (3) R2 as the 3-nitro group also plays 
an important role in the activities against the HIV viral 
replication. For example, when R3 = H and R1 = 6-Me, 
the corresponding compound 10 usually displayed more 
potent anti-HIV-1 activity (TI = 116.23); When R3 = Me 
and R1 = H or 6-Me, the corresponding compounds 18 
and 23 also exhibited the most remarkable anti-HIV-1 
activity (TI >769.23 and >645.16, respectively). (4) 
It is noteworthy that introduction of R3 as the methyl 
group and R2 as the hydrogen group could result in more 
potent compounds. For example, the EC50 and TI values 
of compounds 14, 19, 24 and 27 were 0.52, 0.49, 0.67, 
0.50 μg/mL, and >384.61, >408.16, >298.50, 249.86, 
respectively. This suggested that introduction of R3 as 
the methyl group could be taken into account for further 
preparation of these kinds of compounds as anti-HIV-1 
agents.
EXPERIMENTAL SECTION
Compound purity assessment
The purity of N-arylsulfonyl-3-acylindole benzoyl 
hydrazone derivatives 1-32 were recorded on a Shimadzu 
LC-15C liquid chromatograph [SPD-15C UV-vis 
spectrophotometric detector (190-700 nm)] using a flow 
rate of 1.0 mL/min (MeOH/H2O = 5/1) and a Hypersil 
ODS C18 column (5 μm, 4.6 × 150 mm) as the stationary 
phase, and all compounds purity were >95%.
Anti-HIV-1 activity assay
Cells and virus
The cell line (C8166) and the laboratory-derived 
virus (HIV-1 IIIB) were obtained from the Medical Research 
Council, AIDS Reagent Project, London, UK. C8166 was 
maintainedin RPMI-1640 medium supplemented with 
10% heat-inactivated newborn calf serum (Gibco, Grand 
Island, NY, USA). The cells used in all experiments were 
in log-phasegrowth. The 50% HIV-1 IIIB tissue culture 
infectious dose (TCID50) in C8166 cells was determined 
and calculated by the Reed and Muench method. 
Virusstocks were stored in small aliquots at -70oC.
MTT-based cytotoxicity assay
Cellular toxicity of compounds 1-32 on C8166 
cells was assessed by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) method as 
described previously. Briefly, cells were seeded in a 96-
well microtiter plate in the absence or presence of various 
concentrations of compounds in triplicate and incubated 
at 37 oC in a humid atmosphere of 5% CO2 for 3 days. The 
supernatants were discarded and MTT reagent (5 mg/mL in 
PBS) was added to each well, then incubated for 4 h, after 
which 100 μL of 50% DMF–20% SDS was added. After 
the formazan was dissolved completely, the plates were 
read on a BioTekElx800 ELISA reader (BioTek, Winooski, 
VT, USA) at 595/630 nm. Thecytotoxic concentration that 
caused the reduction of viable C8166cells by 50% (CC50) 
was determined from the dose-response curve.
Syncytia assay
In the presence of 100 μL of various concentrations 
of compounds 1-32, C8166 cells (4×105/mL) were infected 
with HIV-1IIIB at a multiplicity of infection (M.O.I) of 
0.06. The final volume per well was 200 μL. Control 
assays were performed without the test compounds in 
HIV-1IIIB infected and uninfected cultures. After 3 days 
of culture, the cytopathic effect (CPE) was measured by 
counting the number of syncytia. Percentage inhibition 
of syncytia formationwas calculated, and the 50% 
effective concentration (EC50) was calculated. 3′-Azido-
3′-deoxythymidine (AZT; Sigma-Aldrich, St. Louis, MO, 
USA) was used as a positive control. The therapeutic index 
(TI) was calculated as CC50/EC50.
CONCLUSIONS
In the present study, 32 N-arylsulfonyl-3-acylindole 
benzoyl hydrazone derivatives were prepared and 
screened in vitro as HIV-1 inhibitors for the first time. 
Zhiping C., Yuee T., Shengming L., Mei H., Genqiang C.
Braz. J. Pharm. Sci. 2018;54(4):e17543Page 6 / 7
Among the reported analogues, compounds 10, 14, 
18-20, 23, 24 and 27 exhibited significant anti-HIV-1 
activity with EC50 values of 1.02, 0.52, 0.26, 0.49, 1.65, 
0.31, 0.67 and 0.50 μg/mL, and TI values of 116.33, 
>384.61, >769.23, >408.16, >121.21, >645.16, >298.50 
and >249.86, respectively. Especially N-(3-nitro)
phenylsulfonyl-3-acetylindole benzoyl hydrazone (18) 
and N-(3-nitro)phenylsulfonyl-3-acetyl-6-methylindole 
benzoyl hydrazone (23) displayed the highest anti-HIV-1 
activity.
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